News
Zacks.com on MSN2d
Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.
The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...
The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...
Healthcare Asia Magazine on MSN1d
7MM triple-negative breast cancer market eyes 4.7% CAGR growth until 2034The sector’s expansion is attributed to rising incidence rates. The triple-negative breast cancer (TNBC) market across the ...
Bristol Myers SquibbBMY announced a strategic collaboration agreement with BioNTechBNTX for the global co-development and ...
Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.
Zacks Investment Research on MSN6d
Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...
Read about BioNTech SE ADR (BNTX:XNAS) stock and today's latest news and financial updates.
Bristol Myers is making waves after a period of pressure. The stock jumped 6.3% recently, outperforming its industry and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback